Phase 2/3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of REC-2282 in Participants with NF2 Mutated Meningiomas
Clinical Trial Grant
Awarded By
Recursion Pharmaceuticals, Inc
Start Date
June 7, 2022
End Date
January 13, 2026
Awarded By
Recursion Pharmaceuticals, Inc
Start Date
June 7, 2022
End Date
January 13, 2026